Company Quick10K Filing
AbbVie
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 1,484 $100,912
10-K 2020-02-21 Annual: 2019-12-31
10-Q 2019-11-06 Quarter: 2019-09-30
10-Q 2019-08-05 Quarter: 2019-06-30
10-Q 2019-05-03 Quarter: 2019-03-31
10-K 2019-02-27 Annual: 2018-12-31
10-Q 2018-11-07 Quarter: 2018-09-30
10-Q 2018-08-07 Quarter: 2018-06-30
10-Q 2018-05-04 Quarter: 2018-03-31
10-K 2018-02-16 Annual: 2017-12-31
10-Q 2017-11-07 Quarter: 2017-09-30
10-Q 2017-08-07 Quarter: 2017-06-30
10-Q 2017-05-05 Quarter: 2017-03-31
10-K 2017-02-17 Annual: 2016-12-31
10-Q 2016-11-07 Quarter: 2016-09-30
10-Q 2016-08-05 Quarter: 2016-06-30
10-Q 2016-05-06 Quarter: 2016-03-31
10-K 2016-02-19 Annual: 2015-12-31
10-Q 2015-11-06 Quarter: 2015-09-30
10-Q 2015-08-07 Quarter: 2015-06-30
10-Q 2015-05-08 Quarter: 2015-03-31
10-K 2015-02-20 Annual: 2014-12-31
10-Q 2014-11-07 Quarter: 2014-09-30
10-Q 2014-08-07 Quarter: 2014-06-30
10-Q 2014-05-09 Quarter: 2014-03-31
10-K 2014-02-21 Annual: 2013-12-31
10-Q 2013-11-12 Quarter: 2013-09-30
10-Q 2013-05-08 Quarter: 2013-03-31
10-K 2013-03-15 Annual: 2012-12-31
8-K 2020-02-11 Leave Agreement
8-K 2020-02-07 Earnings, Exhibits
8-K 2020-01-27 Other Events, Exhibits
8-K 2019-12-20 Other Events, Exhibits
8-K 2019-11-21 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2019-11-18 Other Events, Exhibits
8-K 2019-11-12 Enter Agreement, Exhibits
8-K 2019-11-07 Other Events, Exhibits
8-K 2019-11-07 Other Events, Exhibits
8-K 2019-11-06 Regulation FD, Other Events, Exhibits
8-K 2019-11-01 Earnings, Exhibits
8-K 2019-10-25 Other Events, Exhibits
8-K 2019-10-17
8-K 2019-09-26 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2019-09-17 Enter Agreement, Exhibits
8-K 2019-09-16 Regulation FD, Exhibits
8-K 2019-09-16 Other Events, Exhibits
8-K 2019-08-27 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2019-07-26 Earnings, Exhibits
8-K 2019-07-12 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2019-06-25 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2019-05-03 Shareholder Vote
8-K 2019-04-25 Earnings, Exhibits
8-K 2019-01-25 Earnings, Exhibits
8-K 2019-01-04 Impairments
8-K 2019-01-04
8-K 2018-12-13 Officers, Exhibits
8-K 2018-11-02 Earnings, Exhibits
8-K 2018-10-16 Officers
8-K 2018-09-13 Enter Agreement, Leave Agreement, Off-BS Arrangement, Exhibits
8-K 2018-08-31 Enter Agreement, Leave Agreement, Off-BS Arrangement, Exhibits
8-K 2018-07-27 Earnings, Exhibits
8-K 2018-05-17 Enter Agreement, Off-BS Arrangement, Exhibits
8-K 2018-05-04 Shareholder Vote
8-K 2018-05-01 Suspend Trading, Exhibits
8-K 2018-04-26 Earnings, Other Events, Exhibits
8-K 2018-01-26 Earnings, Exhibits

AbbVie Financials

ABBV Metrics, Comps, Filings

Annual | Quarterly

Business

AbbVie(1) is a global, research-based biopharmaceutical company. AbbVie develops and markets advanced therapies that address some of the world's most complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; as well as other serious health conditions. AbbVie also has a pipeline of promising new medicines in clinical development across such important medical specialties as immunology, oncology and neuroscience, with additional targeted investment in cystic fibrosis and women's health.

AbbVie was incorporated in Delaware on April 10, 2012. On January 1, 2013, AbbVie became an independent, publicly-traded company as a result of the distribution by Abbott Laboratories (Abbott) of 100% of the outstanding common stock of AbbVie to Abbott's shareholders.

AbbVie operates in one business segment-pharmaceutical products. See Note 15 to the Consolidated Financial Statements and the sales information related to HUMIRA, IMBRUVICA and MAVYRET included under Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations."


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Abbott (ABT) 149,087 57% 22.9 4% 68,427 36,741 30,935 17,651 2,895 7,217 164,940
Eli Lilly (LLY) 106,241 77% 11.8 20% 38,666 35,809 23,229 17,810 7,843 9,937 117,668
AbbVie (ABBV) 100,912 77% 18.0 7% 57,142 65,708 32,624 25,254 4,118 7,085 127,359
Beigene (BGNE) 98,573 88% -152.1 -31% 2,150 579 434 383 -664 -642 97,723
Bristol Myers Squibb (BMY) 73,829 53% 8.4 11% 55,163 39,012 23,857 12,640 6,226 8,365 69,858
Celgene (CELG) 67,154 96% 10.4 13% 39,183 29,132 16,354 15,736 5,271 7,702 79,730
GW Pharmaceuticals (GWPH) 64,239 88% -1,554.6 -6% 843 114 114 100 -50 -41 63,656
Allergan (AGN) 54,767 85% 80.8 -4% 123,846 38,273 15,678 13,341 -5,356 939 75,841
Zoetis (ZTS) 54,569 67% 25.9 13% 10,986 8,575 6,046 4,046 1,375 2,291 59,314
Sanofi (SNY) 52,845 0% 111,408 0 0 0 0 52,184
Vertex Pharmaceuticals (VRTX) 46,842 87% 16.9 33% 7,033 1,964 3,454 2,990 2,355 2,569 43,540
Regeneron Pharmaceuticals (REGN) 35,984 0% 15.2 16% 13,174 3,418 7,237 0 2,069 2,295 34,925
Alexion Pharmaceuticals (ALXN) 28,246 71% 15.7 9% 14,568 4,404 4,499 3,191 1,334 1,835 28,827
Biomarin Pharmaceutical (BMRN) 15,774 79% 680.7 -3% 4,393 1,432 1,533 1,213 -110 24 16,336
Elanco Animal Health (ELAN) 12,085 52% 30.6 2% 8,857 3,591 3,073 1,591 144 460 14,098
Mylan (MYL) 9,779 34% 8.3 0% 31,817 19,914 11,245 3,793 34 2,748 22,896
Teva (TEVA) 9,708 44% -13.7 -6% 59,424 44,173 17,720 7,741 -3,851 -2,437 33,498
Sarepta Therapeutics (SRPT) 9,465 0% -16.1 -33% 1,748 649 345 0 -570 -518 8,352
Ionis Pharmaceuticals (IONS) 9,097 57% 30.7 17% 2,878 1,421 799 459 495 287 8,825
Sage Therapeutics (SAGE) 8,814 51% -14.1 -47% 1,316 113 2 1 -613 -612 8,646

Balance Sheet ($MM)2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash9,5958,3488,3995,1009,3037,289
Accounts Receivable5,384
Inventory1,1501,1241,7191,4441,6051,605
PP&E6,9092,4852,5652,6042,8032,883
Assets29,19827,54753,05066,09970,78659,352
Accounts Payable9338811,5971,4071,4741,546
Long-Term Debt14,29210,56529,24036,44030,95335,002
Liabilities24,70625,80549,10561,46365,68967,798
Stockholders' Equity4,4921,7423,9454,6365,097-8,446
Income Statement ($MM)2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue18,79019,96022,85925,63828,21632,753
Cost of Revenue7,718
Gross Profit25,035
R&D2,8553,2974,2854,3664,98210,329
SG&A5,3527,7246,3875,8556,2757,399
Tax1,3054981,1083,5632,418-490
Net Income5,9535,3095,687
Cash Flow ($MM)2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating6,2673,5497,5357,0419,96013,427
Cash Investing879-926-12,936-6,074-274-1,006
Cash Financing-3,442-3,2935,752-3,928-5,512-14,396